Design, synthesis and evaluation of XZH-5 analogues as STAT3 inhibitors

Philias Daka, Aiguo Liu, Chamini Karunaratne, Erika Csatary, Cameron Williams, Hui Xiao, Jiayuh Lin, Zhenghu Xu, Richard C. Page, Hong Wang

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Inhibition of the signaling pathways of signal transducer and activator of transcription 3 (STAT 3) has shown to be a promising strategy to combat cancer. In this paper we report the design, synthesis and evaluation of a novel class of small molecule inhibitors, that is, XZH-5 and its analogues, as promising leads for further development of STAT3 inhibitors. Preliminary SARs was established for XZH-5 and its derivatives; and the binding modes were predicted by molecular docking. Lead compounds with IC50 as low as 6.5 μM in breast cancer cell lines and 7.6 μM in pancreatic cancer cell lines were identified.

Original languageEnglish (US)
Pages (from-to)1348-1355
Number of pages8
JournalBioorganic and Medicinal Chemistry
Issue number6
StatePublished - Mar 15 2015
Externally publishedYes


  • Inhibitor
  • Molecular docking
  • SARs
  • SH2
  • STAT3
  • Small organic molecule

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Design, synthesis and evaluation of XZH-5 analogues as STAT3 inhibitors'. Together they form a unique fingerprint.

Cite this